

INVESTOR PRESENTATION AND OVERVIEW OF APPENDIX 4C

Bio-Gene Technology Limited (ASX: BGT, 'Bio-Gene' or 'the Company'), an agtech development company enabling the next generation of novel insecticides, is pleased to provide investors with access to our updated Investor Presentation and an overview of our recently released Appendix 4C.

Richard Jagger, Bio-Gene's CEO/MD comments on Bio-Gene's Appendix 4C and provides an update on the Company's progress. Review the video [here](#).

A copy of the latest Investor Presentation can be seen [here](#).

Approved for release by the Managing Director.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger
Chief Executive Officer
P: 03 9068 1062
E: bgt.info@bio-gene.com.au

Roger McPherson
Chief Financial Officer
P: 03 9068 1062
E: bgt.info@bio-gene.com.au

IR/Media

Rudi Michelson
Monsoon Communications
P: 03 9620 3333
E: rudim@monsoon.com.au

About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, animal health and consumer applications. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

Flavocide™ and **Qcide™** are trademarks of Bio-Gene Technology Limited.